Advertise on podcast: The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Delayed release on October 24, 2026 of the Friday, October 23 edition. News and relative-date references are as of October 23. Novartis's investigational remibrutinib cut MS relapse rates 35.2% and 31.2% versus teriflunomide; Biokin's Bristol Myers Squibb/SystImmune-partnered iza-bren improved breast cancer PFS. Jazz/BeOne's Ziihera (zanidatamab), licensed from Zymeworks, has mature gastroesophageal survival data, while Tango reports pancreatic cancer responses with vopimetostat and Revolution Medicines' daraxonrasib. Johnson & Johnson's Tecvayli (teclistamab) moves earlier in European myeloma treatment, as we examine BMS's zola-cel safety in MS and Alnylam's brezosiran target engagement in Huntington's. Plus Bolt's Prana acquisition and Treasury's proposed biotech investment rules. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

The Pharma Closeout's UEG Week 2026 Debrief covers the readouts from United European Gastroenterology Week in Barcelona that matter for drug, device and payer strategy. Takeda's VERDICT, the first randomized treat-to-target strategy trial in ulcerative colitis, and the new STRIDE-III guidance sharpen what IBD treatment should aim at, and what that means for how therapies win switches. Then the orals (Abivax's obefazimod ahead of its NDA, Gilead's emvistegrast dose curve, J&J's icotrokinra), the TL1A race with Teva and Sanofi's first 44-week duvakitug data, the incumbents' franchise defense from AbbVie and J&J, Tremfya at week 48 in Crohn's with fistulas, and a gastroparesis drug heading to Phase 3. Plus what to watch: AbbVie's October 30 results, AASLD from November 5 and the November 27 PBC decision. 0:00 Cold open and introduction 0:50 Story of the Congress: the target, not the molecule (Takeda's VERDICT, STRIDE-III, PROFILE) 5:06 The orals: obefazimod, emvistegrast, icotrokinra and OD-001 8:38 The TL1A race: Teva and Sanofi's duvakitug 10:01 Franchise defense: AbbVie, J&J, Spyre and the biosimilar squeeze 13:26 The IL-23 incumbents: Tremfya in fistulizing Crohn's, Skyrizi's subcutaneous induction 15:26 Beyond IBD: gastroparesis, EoE and the liver 17:27 What to watch: AbbVie's results, AASLD and the PBC decision Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

October 22, 2026 edition, released October 23. Reporting reflects the October 22 research cutoff. Merck and Moderna's investigational intismeran autogene, added to Keytruda (pembrolizumab) after surgery for high-risk cutaneous melanoma, posted a 0.58 hazard ratio for recurrence or death versus placebo plus Keytruda; overall survival is immature. AbbVie's investigational lutikizumab beat placebo in a Phase 3 hidradenitis suppurativa trial, 31.4% versus 23.4% on HiSCR75. The daily roundup covers BioNTech's planned pairing of pumitamig with Gilead's Trodelvy (sacituzumab govitecan), Menarini subsidiary Stemline's GIM-621 license from Georgiamune, Cencora's American Oncology Network deal and Roche's removal of RG6540 from its Phase 1 pipeline. It also covers Krystal Biotech's Vyjuvek (beremagene geperpavec) storage update, Biohaven's statement, reported by Dow Jones, that FDA accepted its Vyglxia resubmission, and QIAGEN's agreed EQT-led acquisition. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

October 21, 2026 edition, released October 22. Relative dates in the audio refer to October 21. Roivant's Priovant reports two positive Phase 3 trials of oral brepocitinib in non-infectious uveitis, run through a mandatory steroid taper. F2G and Shionogi add kidney, liver and hospital-stay detail from olorofim's OASIS trial, where survival was noninferior rather than better. Also in the daily roundup: Alcon completes its Neurotech acquisition, the European Commission approves perioperative Keytruda plus Padcev regardless of cisplatin eligibility, Summit and ECOG-ACRIN set up a trial of ivonescimab in biliary tract cancer, Roche discloses fenebrutinib lesion imaging ahead of its MSToronto presentation, TG releases data on a single-infusion Briumvi start, OpenAI acquires Orchestra Bio, and FDA's warning letter to Baxter becomes public. Sources:https://www.biospace.com/press-releases/roivant-and-priovant-announce-positive-results-in-clarity-1-and-clarity-2-phase-3-trials-for-brepocitinib-in-non-infectious-uveitis-niuhttps://www.sec.gov/Archives/edgar/data/1635088/000114036126034854/ef20081283_ex99-1.htmhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5023a17b-e96a-67d4-e063-6394a90a14a7https://www.shionogi.com/global/en/news/2026/10/e20261021_3.htmlhttps://www.biospace.com/press-releases/alcon-acquires-neurotech-and-encelto-the-only-fda-approved-treatment-for-mactel-type-2https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-resectable-muscle-invasive-bladder-cancer-mibc/https://www.prnewswire.com/news-releases/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer-302915469.htmlhttps://www.roche.com/media/releases/med-cor-2026-10-21https://clinicaltrials.gov/study/NCT04544449https://www.tgtherapeutics.com/wp-content/uploads/2026/10/ENHANCE-600-mg_ECTRIMS-2026_Final-Poster_PDF.pdfhttps://openai.com/index/openai-to-acquire-orchestra-bio/https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-first-pd-1-inhibitor-plus-antibody-drug-conjugate-regimen-for-adults-with-cisplatin-ineligibl/https://www.roche.com/media/releases/med-cor-2026-09-30

FDA approved GSK's Hibsago (bepirovirsen) for selected adults with chronic hepatitis B without cirrhosis, opening a possible path off long-term treatment after a staged treatment and testing process. We examine who qualifies, the B-Well results and the boxed safety warnings. Amgen and AstraZeneca's detailed Phase 3 CROSSING results show Tezspire's biopsy remission and swallowing outcomes in eosinophilic esophagitis, where Dupixent is already established. The daily roundup covers Rapport's RAP-219 bipolar mania results; TriGemX's proposed SPAC combination to fund migraine development; Veradermics' second Phase 3 hair-loss study; UroGen's UGN-103 filing acceptance; Nouscom's financing for cancer interception; Ambrose's AM-Pharma acquisition; and ICER's new-drug launch-price and prescription-access findings. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

FDA granted accelerated approval to GSK's Jemperli (dostarlimab) for biomarker-defined locally advanced rectal cancer, with continued surveillance required for responders. Disc Medicine's bitopertin met both Phase 3 APOLLO co-primary endpoints in erythropoietic protoporphyria after an earlier FDA rejection. The roundup covers Roche and Hansoh's oncology ADC deal, Merck KGaA's acquisition agreement for Silence Therapeutics in polycythemia vera, Lilly's Omvoh (mirikizumab) and Gilead's emvistegrast in ulcerative colitis. Also: AbbVie's ABBV-466 Crohn's data and EyePoint's DURAVYU Phase 3 miss in wet AMD and restructuring. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

The Pharma Closeout's AAO 2026 Debrief covers the readouts from the American Academy of Ophthalmology meeting in New Orleans that matter for drug, device and payer strategy. Kodiak's DAYBREAK and Ocular Therapeutix's SOL-1 show retina's durability race: fewer injections than fixed-schedule aflibercept, with Eylea HD and Vabysmo untested and the old standard going biosimilar. Belite Bio's tinlarebant heads to a February FDA decision in Stargardt disease, Beacon's VISTA data back a gene therapy filing, and Nanoscope's optogenetic therapy holds at four years. Plus geographic atrophy's next bets, two GLP-1 eye studies pointing in opposite directions, Lytenava's billing-code gap, and what to watch: the October 30 myopia advisory committee and the February 12 Stargardt decision. 0:00 Cold open and introduction 1:06 Story of the Congress: retina's durability race (Kodiak, Ocular, EyePoint) 4:29 The old standard goes biosimilar 5:08 Inherited retinal disease moves into the FDA queue: Belite, Beacon, Nanoscope 8:00 Geographic atrophy: PRIMA, K8 and OCU410 9:45 GLP-1 drugs and the eye: two studies, two directions 11:01 Roundup: Lytenava's billing code, Oculis, SpyGlass 12:14 What to watch: the myopia advisory committee and the Stargardt decision Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Fractyl Health reports that its investigational Revita met the six-month co-primary endpoint of the double-blind, sham-controlled REMAIN-1 pivotal study in adults who lost weight on tirzepatide and then stopped it; the twelve-month co-primary is expected in early 2027. Liquidia and United Therapeutics settled all pending patent litigation: Yutrepia stays available for PAH, Liquidia has asked FDA to remove PH-ILD from the label, and total obligations come to $380.7 million. Alex Mercer and Maya Patel cover Revita's safety and missing-data context, then turn to Verdiva's terminated switch-maintenance study, Biomea's BMF-650 Phase 1 data with its confined-placebo caveat, CHMP opinions for Lilly's oral Foundayo and for broadening Tryngolza in severe hypertriglyceridemia, Roche's ALK7 RNAi license from Rona, Zealand's AI-designed protein deal with Generate, and OMass Therapeutics' Series C. Also covered: Alaunos' completed Velaris acquisition and separate private placement; BMS's split admilparant Phase 3 and Syndax's IPF exit; Verastem's KRAS G12D pancreatic cohort and planned first-line Phase 3; CHMP opinions for Rasonque and Talvey; BNT113, Anktiva's papillary-only expansion and Nurix; tab-cel's accepted FDA resubmission; CHMP's confirmed negative opinion on re-examination for Omeros's narsoplimab; KB113 and RYZ101; Modus's sevuparin enrollment pause, Estuary's launch and Novartis's terminated iptacopan lupus nephritis study; maralixibat, obexelimab and garetosmab data; the Zilbrysq autoinjector, ARO-MAPT and Vanda's VQW-765 result and program hold; Anaphylm's FDA review date; FDA approvals for Enspryng in thyroid eye disease and RYZUMVI in presbyopia; interim six-year MIUDELLA data; Galderma's agreement to buy ZO Skin Health; Osivax's flu vaccine result; Pfizer's Enodia deal; IPOs from Iambic and City Therapeutics; China's export-control registration and draft catalog; a CMS proposed rule with PBM provisions; FDA's rare-disease framework initiative; and Marengo's upcoming ESMO presentation. The episode closes on the week's shared CHMP meeting and its different outcomes, the still-open question of weight maintenance after obesity drugs stop, and financings at different stages of completion. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.

Friday, October 16 edition. Roche’s Enspryng wins FDA approval for thyroid eye disease as a home injection, while Omeros faces another negative European opinion for narsoplimab and plans to end compassionate use there. Alex Mercer and Maya Patel unpack the patient, evidence and commercial implications. Also covered: Talvey’s proposed earlier-line use in Europe; Arrowhead’s early ARO-MAPT tau data in healthy volunteers; Foundayo’s European committee recommendations; RYZUMVI’s presbyopia approval; China’s draft drug-technology export controls; and Labcorp’s agreement to acquire select BioReference assets. Recorded for Friday, October 16; released October 17 after a freshness check.

FDA expanded ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) to papillary-only bladder cancer by extrapolating earlier evidence. Vanda paused VQW-765 after its Phase 3 social-anxiety trial missed, while Vir and Gilead agreed a solid-tumor T-cell engager collaboration. The roundup covers a European recommendation for Revolution Medicines' daraxonrasib in pancreatic cancer, Osivax's OVX836 influenza-vaccine miss, and Alvotech/Advanz's AVT29 high-dose Eylea (aflibercept) biosimilar filing. Galderma's planned ZO Skin Health acquisition and OrbiMed's $3 billion in fund commitments round out the day. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

October 14, 2026 edition, released October 15, 2026. BioNTech's BNT113 missed progression-free survival in its pivotal head and neck cancer trial, leaving overall survival as the remaining path to a positive result. Roche licensed Rona Therapeutics' undisclosed ALK7-targeting RNAi obesity candidate—a fat-cell approach with most potential deal value contingent on milestones. Johnson & Johnson raised full-year guidance as newer medicines offset Stelara erosion; the roundup also covers FDA review of FYB206, a proposed Keytruda (pembrolizumab) biosimilar, Syndax ending axatilimab in IPF, 84-week Pasatru (garetosmab) data in FOP, and Tremfya (guselkumab) analyses in Crohn's perianal fistulas. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Monday, October 12, 2026 edition, released Tuesday, October 13, 2026. News checked through October 13, 2026; no material updates to the stories below were found. Bristol's admilparant met its Phase 3 lung-function endpoint at the lower dose, while the higher dose missed significance in idiopathic pulmonary fibrosis. Its acquired RYZ101 program also delivered a Phase 3 win in neuroendocrine tumors after lutetium therapy, with benefit size still undisclosed. Mirum's LIVMARLI (maralixibat) reduced childhood itch in EXPAND, while the roundup covers First Tracks' ANB033 in celiac disease, Sebela's tegoprazan in reflux, Zenas' obexelimab in IgG4-related disease, Claris' eye-drop data and Ascelia's Orviglance regulatory path. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Merck's remigromig met BRUNELLO's noninferiority bar in diabetic macular edema, but showed no superiority and a notable safety imbalance. AstraZeneca completed its $2 billion Summit Therapeutics investment around ivonescimab combinations, while Roche's vamikibart entered FDA review with mixed Phase 3 evidence behind the filing. The Sunday, October 11 Week in Review—released Monday, October 12—also spans oncology, cardiometabolic and rare disease, respiratory and neuroscience, immunology, vaccines, infectious disease, access and medicine safety. Across 45 news stories and three forward watches, Alex and Maya separate completed events and clinical results from filings, plans and pending catalysts. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

The Pharma Closeout's MDS 2026 Debrief covers the readouts from the International Parkinson and Movement Disorder Society congress in Seoul that matter for drug, diagnostic and payer strategy. Biogen and Denali'sLUMA and Bial's ACTIVATE showed full data on two genetic bets in Parkinson's disease that missed, and we look at what still stands: Arvinas's LRRK2 degrader, a spinal-fluid marker that could help pick patients, and Roche's prasinezumab Phase 3. AbbVie's newly approved Juvmo meets ICER's numbers, and we put Cerevance's solengepras result against the approved add-ons. Plus Syntara's trial in REM sleep behaviour disorder, a skin test for alpha-synuclein, Praxis's essential tremor drug, Teva's ecopipam in Tourettesyndrome, Neurocrine's five-year valbenazine data, and what to watch: the Huntington's congress, ICER's final report, Austedo's Medicare price and Praxis's FDA date. 0:00 Cold open and introduction1:02 Story of the Congress: two genetic bets fall in full data4:03 The remaining bets: Arvinas's degrader, a spinal-fluid marker, Roche's prasinezumab6:00 AbbVie's Juvmo meets ICER8:11 Solengepras: how to read 37 minutes9:48 Before diagnosis: Syntara's REM sleep trial and a skin test11:48 Beyond Parkinson's: essential tremor, Tourette syndrome, Huntington's disease14:15 What to watch: Huntington's congress, ICER's final report, Austedopricing, Praxis's FDA date Alex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com.

Friday, October 9 edition, released late Saturday, October 10. FDA approved Hovilpri (pritelivir) for immunocompromised adults with stubborn herpes simplex lesions, but the oral drug is not yet available and is expected in the U.S. before the end of 2026. Biohaven agreed to license rights for parts of Asia to Phase 3 Graves' disease candidate BHV-1300 to Ono for $80 million at closing, plus a separate conditional $20 million; the deal is not evidence of efficacy. Also: J&J reports two-year Icotyde PASI 90 results without a long-term Sotyktu comparison, and Pennsylvania details GSK's $800 million-plus Upper Merion manufacturing expansion. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.